What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of study are Internal medicine, Transplantation, Surgery, Gastroenterology and Hematopoietic stem cell transplantation.
Fludarabine, Leukemia, Regimen, Busulfan and Cyclophosphamide are subfields of Internal medicine in which his conducts study.
Borje S. Andersson has researched Transplantation in several fields, including Immunology, Cord blood, Pathology, CD34 and Preparative Regimen.
His work in Surgery covers topics such as Bone marrow which are related to areas like Radiation therapy.
His Gastroenterology research includes themes of Tacrolimus, Cumulative incidence, Allogeneic transplantation, Lymphoma and Transplantation Conditioning.
His Hematopoietic stem cell transplantation study combines topics from a wide range of disciplines, such as Progenitor cell, Immunosuppression and Graft-versus-host disease.
His most cited work include:
- Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy (1097 citations)
- Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. (896 citations)
- Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (572 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Transplantation, Busulfan, Surgery and Gastroenterology are his primary areas of study.
Internal medicine and Oncology are commonly linked in his work.
His research in Transplantation tackles topics such as Leukemia which are related to areas like Myeloid.
His Busulfan research is multidisciplinary, incorporating perspectives in Pharmacokinetics, Pharmacology, Myeloid leukemia, Gemcitabine and Clofarabine.
His Surgery research is multidisciplinary, incorporating elements of Transplantation Conditioning and Bone marrow.
His study explores the link between Gastroenterology and topics such as Cumulative incidence that cross with problems in Univariate analysis.
He most often published in these fields:
- Internal medicine (62.45%)
- Transplantation (47.67%)
- Busulfan (36.19%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (62.45%)
- Busulfan (36.19%)
- Transplantation (47.67%)
In recent papers he was focusing on the following fields of study:
Borje S. Andersson spends much of his time researching Internal medicine, Busulfan, Transplantation, Oncology and Hematopoietic stem cell transplantation.
His Internal medicine research includes elements of Gastroenterology and Surgery.
He has included themes like Clinical trial, Melphalan, Gemcitabine, Fludarabine and Clofarabine in his Busulfan study.
Borje S. Andersson interconnects Chemotherapy regimen, Blast Count, Randomized controlled trial, Hazard ratio and Bone marrow in the investigation of issues within Transplantation.
Borje S. Andersson focuses mostly in the field of Oncology, narrowing it down to topics relating to Leukemia and, in certain cases, Myeloid.
His research investigates the connection between Hematopoietic stem cell transplantation and topics such as Immunology that intersect with problems in Hemorrhagic cystitis.
Between 2014 and 2021, his most popular works were:
- Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation (91 citations)
- Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin e patients from haploidentical donors (65 citations)
- Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. (45 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Borje S. Andersson mainly focuses on Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Busulfan and Oncology.
He combines subjects such as Gastroenterology and Surgery with his study of Internal medicine.
In his study, European LeukemiaNet is inextricably linked to Transplantation Conditioning, which falls within the broad field of Surgery.
His Transplantation research integrates issues from Randomized controlled trial, Intention-to-treat analysis, Myelodysplastic syndromes, Hazard ratio and Comorbidity.
His studies in Hematopoietic stem cell transplantation integrate themes in fields like Incidence, Immunology, Bone marrow and Graft-versus-host disease.
His Busulfan study combines topics from a wide range of disciplines, such as Mucositis, Pharmacokinetics, Melphalan, Regimen and Fludarabine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
